Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 9/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6348272 | 1.00 | CAPN1 (0.40) | CAPN1PSMB8FPR2GPR139POLB | |
| SCHEMBL6347128 | 0.93 | POLB (0.39) | CAPN1POLBALDH1A1 | |
| SCHEMBL6347131 | 0.93 | POLB (0.39) | CAPN1POLBALDH1A1 | |
| SCHEMBL6351923 | 0.90 | OXTR (0.39) | CAPN1POLBALDH1A1 | |
| SCHEMBL6351926 | 0.90 | OXTR (0.39) | CAPN1POLBALDH1A1 | |
| SCHEMBL6346809 | 0.86 | BCHE (0.38) | PSMB8FPR2GPR139ADORA2AALDH1A1 | |
| SCHEMBL6356918 | 0.81 | POLB (0.38) | CAPN1POLBALDH1A1 | |
| SCHEMBL6356914 | 0.81 | POLB (0.38) | CAPN1POLBALDH1A1 | |
| SCHEMBL6349674 | 0.80 | GPR139 (0.39) | CAPN1PSMB8FPR2GPR139ADORA2A | |
| SCHEMBL6349670 | 0.80 | GPR139 (0.39) | CAPN1PSMB8FPR2GPR139ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960575-B2 | For use as inhibitors of chymase | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20040097496-A1 | Novel thiazine derivatives | SANTEN PHARMACEUTICAL CO.,LTD. (JP) | 2004-05-20 | — | — | US | disclosed |
| US-6713472-B1 | 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097496-A1 | Novel thiazine derivatives | CMA1, TPSD1, HRH4 | CAPN1 245/4885PSMB8 1086/4885FPR2 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.